Pfizer may be the last major oncology player to put a wager on a PARP inhibitor in prostate cancer, but the New York pharma appears to have a winning regimen, partly thanks to its Astellas-partnered ...

First and only PARP inhibitor plus ARPI combination to demonstrate statistically significant overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer (mCRPC) ...

TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic ...

The PARP inhibitor class is welcoming its second FDA approval in prostate cancer in the span of several weeks. The new approval, for Pfizer, is broader than the first but still limited. The FDA has ...

(RTTNews) - Pfizer (PFE) Thursday reported positive results from the Phase 3 TALAPRO-2 study of Talzenna, an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide) ...

Talzenna (talazoparib) is a brand-name drug that’s prescribed for certain types of breast and prostate cancers in adults. It comes as an oral capsule that’s typically taken once per day. The dosage ...

TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the Europe Union “After years of fighting prostate cancer, it can be ...

(RTTNews) - Pfizer Inc. (PFE) Thursday reported positive topline results from the Phase 3 TALAPRO-2 study of Talzenna in combination with Xtandi in patients with metastatic castration-resistant ...

TALZENNA is approved in over 70 countries, including the U.S., as a once-daily monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer ...

In mCRPC patients, Talzenna + Xtandi cut death risk by 20%, extending median OS to 45.8 months vs. 37.0 months with Xtandi alone. In HRR-mutated mCRPC, Talzenna + Xtandi reduced death risk by 38%, ...